Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE TATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

3

Sheet

1

Complete if Known				
Application Number	09/980,772			
Filing Date	July 31, 2002			
First Named Inventor	Malcolm BRANDON			
Art Unit	1632			
Examiner Name	Joseph T. Woitach			
Attorney Docket Number	78870/00004			

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	er Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		Thomson JA,ltskovitz-Eldor J, Shapiro 55, Waknitz MA,Swiergiel JJ, Marshall VS, Jones JM: Embryonic stem cell lines derived from human blastocysts. Science 1998,282: 1145-1147.		
		Reubinoff BE, Pera MF, Fong CY. Trounson AO, Bongso A: Embryonic stem cell lines from humanblastocysts: somatic differentiation in vitro. Nature Biotechnology 2000,18: 399-404.		
		Smith A6 : Cell therapy: In search of pluripotency. Current Biology 1998,8: R802-804.		
		Solter D: Dolly is a clone-and no longer alone. Nature 1998,394: 315.		
		Wilmut I, Schnieke AE, McWhir J, Kind AJ,Campbell KH: Viable offspring derived from fetal and adult mammalian cells. Nature 1997,385: 810-813.		
		Wakayama T, Perry AC, Zuccotti M, Johnson KR, Yanagimachi R: Full-term development of mice from enucleated oocytes injected with cumulus cell nuclei. Nature 1998,394: 369-374.		
		Mountford PM, Smith AG: Internal ribosome entry sites and dicistronic RNAs inmammalian transgenesis.TlG 1995,11: 179-184.		
		Munsie M, Peura TP, MichalskaA, Trounson AO, Mountford PS: Novel method for demonstrating nuclear contribution in mouse nuclear transfer. Reproduction Fertility and Development 1998,10: 633-637.		
		Cibelli JB, Stice SL, Golueke PJ, Kane JJ, Jerry J, Blackwell C, Ponce de Leon FA,Robl JM: Transgenic bovine chimeric offspring produced from somatic cell-derived stem-like cells. Nature Biotechnology 1998,16: 642-646.		
		Klug MG, Soonpaa MH, Koh GY,Field LJ: Genetically selected cardiomyocytes from differentiating embronic stem cells form stable intracardiac grafts. Journal of Clinical Investigation 1996,98: 216-224.		

Examiner	Date	
Signature	 Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO		Complete if Known			
				Application Number	09/980,772
INFO	DRMATION	DIS	CLOSURE	Filing Date	July 31, 2002
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Malcolm BRANDON
	(Use as many she	ote se n	acassan)	Art Unit	1632
(ose as many sheets as necessary)			acessury)	Examiner Name	Joseph T. Woitach
Sheet	2	of	3	Attorney Docket Number	78870/00004

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>				
		McDonald JW, Liu X-Z, Qu Y, Liu S,Mickey SK, Turetsky D,Gottlieb DI, Choi DW: Transplanted embryonic stem cells survive, differentiate and promote recovery in injured ratspinal cord. Nature Medicine 1999,5: 141 1412.			
		Potocnik AJ, Kohler H, Eichmann K: Hemato-lymphoid in vivo reconstitution potential of subpopulations derived from in vitro differentiated embryonic stem cells. Proc Natl Acad Sci USA 1997,94: 10295-10300.			
		Soria B, Roche E, Berna G, Leon-Quinto T, Reig JA, Matrin F:Insulin-sectreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice. Diabetes 2000.49: 157-162.			
		Barnes FL, Crombie A, Gardner DK, Kausche A,Lacham-Kaplan D, Suikkari A-M, Tiglias J, Wood C, Trounson AO: Blastocyst development and birth after in vitro maturation of human primary oocytes, intracytoplasmic sperm injection and assisted hatching. Hum Reprod 1995, 10: 3243-3247.			
		Robertson EJ: Teratocarcinomas and embryonic stem cells: A practical Approach. Oxford: IRL Press; 1987.			
		Smith AG: Culture and differentiation of embryonic stem cells. J Tiss Cult Meth 1991,13: 89-94.			
		Buehr M, McLaren A: Isolation and culture of primordial germ cells. MethodsEnzymol 1993,225: 58-77.			
		van Eijk MJT, van Rooijen MA, Modina 5, Scesi L, Folkers G, van Tol HTA, Bevers MM, Fisher SR, Lewin HA, Rakacolli D, Galli C, de Vaureix C, Trounson AD, Mummery CL, Gandolfi F: Molecular cloning, genetic mapping, and developmental expression of bovinePOUSFI. Biol Reprod 1999,60: 1093-1103.			
		Agulnik Al, Longepied G, Ty MT, Bishop CE, Mitchell M: Mouse H-Y encoding Smcy gene and its Xchromosomal homolog Smcx. Mamm Genome 1999,10: 926-929.			
		Nagy A, Rossant J, Nagy R, Abramow-Newerly W, Roder JC: Derivation of completely cell culture-derived mice from early-passage embryonic stem cells. ProcNatl Acad Sci USA1993,90: 8424-8428.			

	···		
Examiner		Date	
Signature		Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO		re required to respond to a collection of information unless it contains a valid OMB control number.  Complete if Known			
Substitut				Application Number	09/980,772
INFO	ORMATION	I DIS	CLOSURE	Filing Date	July 31, 2002
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Malcolm BRANDON
	(llee ee many ob	t n		Art Unit	1632
(Use as many sheets as necessary)			ecessary)	Examiner Name	Joseph T. Woitach
Sheet	3	of	3	Attorney Docket Number	78870/00004

	<u> </u>	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Bradley A: Teratocarcinomas and embryonic stem cells: A practical approach. Oxford: IRL Press; 1987.	
		Li M. Pevny L, Lovell-Badge R, Smith A: Generation of purified neural precursors from embryonic stem cellsby lineage selection. Curr Biol 1998, 8: 971-974.	
		Doetschman TC.Eistetter H, Katz M, Schmidt W, Kemler R: The in vitro development of blastocyst-derived embryonic stem cell lines: formation of visceralyolk sac, blood islands and myocardium. J Embryol Exp Morphol 1985,87: 27-45.	
		Beddington RSP, Morgenstem J, Land H. Hogan A: An in situ transgenic enzyme marker for the midgestation mouse embryo and the visualization of innercell mass clones during early embryogenesis. Development 1989, 106: 37-46.	
		Sambrook, J., Fritsch, E. F., Maniatis, T., (1989)Molecular Cloning-A Laboratory Manual, Cold Spring Harbour Laboratory Press, New York); 26 (O'Gorman, S., Fox, D. T.,Wahl, G. M. (1991) Recombinase-mediated gene activation and site-specific integration in mammaliancells. Science 251 (4999), 1351-5).	
		O'Gorman, S., Fox, D.T., Wahl, G.M. (1991) Recombinase-mediated Gene Activation and Site-specific Integration in Mammalian Cells. Science 251 (4999), 1351-5.	
		·	
_			

Examiner	Date	
Signature	 Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.